zentalis_logo_large.jpg
Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor
April 12, 2021 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors
April 10, 2021 13:30 ET | ZENTALIS PHARMACEUTICALS
ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors ZN-c3 was safe and well-tolerated Identified recommended Phase 2 dose for...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update
March 25, 2021 07:00 ET | ZENTALIS PHARMACEUTICALS
Initiated multiple early-stage clinical trials evaluating its oral SERD, ZN-c5, WEE1 inhibitor, ZN-c3 and BCL-2 inhibitor, ZN-d5 Announced strategic collaboration with Tempus to expand and strengthen...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at the AACR Annual Meeting 2021
March 10, 2021 16:30 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities
February 25, 2021 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced a strategic collaboration with Tempus to leverage the company’s...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021
February 24, 2021 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of Directors
February 10, 2021 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK & SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
February 05, 2021 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials
January 06, 2021 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals to Participate In Two Upcoming Investor Conferences
November 12, 2020 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...